IN8bio, Inc. (Nasdaq: INAB), a trailblazer in gamma-delta T cell-based therapies, is turning heads at the forefront of cancer immunotherapy with its latest preclinical findings. Just this week, the company unveiled a poster presentation on its potentially breakthrough next generation γδ T cell-based T cell engager (TCE) platform that will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. This platform, which leverages the unique tumor-targeting capabilities of gamma-delta T cells, represents a significant step forward in precision oncology.
William Ho, CEO, and co-founder of IN8bio stated “T cell engagers are an exciting area of immunotherapy that remains in the early innings of development. We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis and low IL-6 secretion, representing a powerful modality with the potential to overcome the limitations of current CD-3 based engager therapies. Our novel gamma-delta T cell engager platform, presented for the first time at AACR 2025, demonstrates how we can combine the innate tumor-recognition capabilities of gamma-delta T cells with the capacity for significant cell expansion and the specificity of bispecific engagers to drive a potent, targeted immune response against multiple target antigens. These early findings in AML and B-ALL support our broader strategy to harness the unique biology of these cells across a range of cancers.”
Revolutionizing T cell engagers (TCE’s) with Gamma-Delta T Cells
The TCE platform, highlighted through the INB-619 program, demonstrated the ability to selectively target CD19 and destroy B cells without significant secretion of cytokines such as IL-6 that can be strongly associated with adverse events such as cytokine release syndrome or CRS—a feat that underscores its potential to address critical limitations in current CD-3 targeting TCEs. Unlike conventional CAR-T approaches that often cause off-target effects, IN8bio’s technology uses a non-signaling CAR design combined with the natural selectivity of gamma-delta T cells to enhance safety and efficacy. Building on this foundation, IN8bio has also advanced its INB-600 platform, a gamma-delta T cell engager targeting CD19. This platform is designed for broader applications in oncology and autoimmune diseases, nascent market opportunity with significant interest from big pharma. Early preclinical results suggest that these therapies could deliver durable responses with improved safety profiles compared to existing CD3-based engagers.
Market Context and Growth Potential
The global CAR-T cell therapy market is experiencing rapid growth, projected to expand at a compound annual growth rate (CAGR) of 30.5% from 2025 to 2034. This surge is driven by advancements in gene-editing technologies and increasing demand for innovative cancer treatments. Within this competitive landscape, gamma-delta T cell therapies are emerging as a promising modality due to their unique biological properties, including tissue residency and low inflammatory cytokine secretion. Moreover, the broader T-cell therapy market is expected to grow from $51 billion in 2024 to $6.5 billion in 2025 and reach $20.9 billion by 2035. This growth reflects escalating investments in research and development, regulatory approvals, and rising global demand for personalized medicine.
Analyst Sentiment and Financial Position
IN8bio’s strategic advancements have not gone unnoticed by analysts. The company enjoys a “Strong Buy” consensus rating from seven analysts, with 86% recommending it as a top investment pick. Financially, IN8bio reported a net loss of $30.7 million for 2024, but maintains a solid cash position projected to fund operations through March 2026. Recent cost-saving measures and resource optimization efforts further bolster its financial stability.
Don’t Overlook The DeltEx™ Platform…
According to IN8bio’s website, The DeltEx™ platform has enabled a deep pipeline of preclinical and clinical product candidates designed to effectively target and potentially eradicate cancer cells to improve patient outcomes.
- Advanced expertise in the manufacturing of ex-vivo, expanded, activated gamma-delta T cells
- First-in-class proprietary gamma-delta T cell engineering for chemotherapy resistance
- Advanced next-generation, closed-system, scalable, gamma-delta T cell manufacturing
- Broad applicability of our engineered DeltEx cells across multiple solid and hematological cancer indications
The innate and adaptive immune responses play critical roles in the fight against cancer. While both systems possess important functions, the most effective tumor killing occurs when they work together. Gamma-delta T cells are a unique subset of immune cells that sit at the nexus of the innate and adaptive systems and possess properties of both. Their multifunctional nature and complex receptor repertoire allow them to distinguish between healthy and cancerous cells. They can effectively kill tumor cells directly as well as recruit and activate additional immune effector cells to target and eradicate the tumor. Notably, gamma-delta T cells can eliminate cancer cells without prior antigen priming and have the ability to antigen present and trigger a broader immune cell response. These properties make gamma-delta T cells promising candidates for use in for both solid and hematological cancer therapies.
IN8bio’s DeltEx™ platform is designed to overcome many of the challenges associated with the expansion, genetic engineering and scalable manufacturing of gamma-delta T cells, allowing the team to harness their unique properties for cancer therapies. IN8bio’s core technology is a novel concept in cellular therapy, drug resistant immunotherapy, or DeltEx™ DRI, which uses intracellular engineering to generate gamma-delta T cells that are resistant to different classes of chemotherapy. These cells can be used in early and frontline treatment settings where they can survive combinations with therapeutic doses of chemotherapy. Chemotherapy, a mainstay of solid tumor treatment, can deplete and damage immune cells, including gamma-delta T cells, limiting their ability to seek and kill tumors. Chemotherapy treatment can also result in the selection of residual tumor cells that are chemotherapy resistant, which leads to disease recurrence. They have leveraged their proprietary genetic modifications to protect their DeltEx™ DRI cells from chemotherapy-induced damage, allowing for their concomitant delivery with chemotherapy so they can identify and kill residual tumor cells when the tumor is experiencing maximum chemotherapy-induced stress. This DeltEx™ DRI approach is the basis for several of our programs, including INB-200 and INB-400.
Looking Ahead At IN8bio…
As IN8bio continues to push the boundaries of cancer immunotherapy, its focus remains on delivering transformative therapies for hard-to-treat cancers like glioblastoma and acute myeloid leukemia (AML). With ongoing clinical trials demonstrating durable remissions—100% of AML patients treated with the INB-100 program remain relapse-free—the company seems to be well-positioned to make a meaningful impact on patient outcomes while seeking to drive shareholder value. Look for additional clinical updates this summer. In summary, IN8bio’s innovative platforms not only highlight its scientific ingenuity but also place it at the vanguard of a rapidly evolving market poised for exponential growth. Investors and stakeholders alike will be watching closely as the company continues to advance its pipeline and redefine possibilities in cancer treatment.
Further Afield, But Close To Home!
Sanofi To Acquire DR-0201, a targeted bispecific myeloid cell engager (MCE)…
Sanofi (SNY) and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted phagocytosis. Recent early clinical study data in autoimmune diseases suggest that deep B-cell depletion might have the potential to reset the adaptive immune system, leading to sustained treatment-free remission in patients with refractory B-cell mediated autoimmune diseases such as lupus, where significant unmet medical needs remain. Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and potential future payments totaling $1.3 billion upon achievement of certain development and launch milestones. Learn more here.
About Dren Bio
Dren Bio is a privately held, clinical-stage biopharmaceutical company pioneering the discovery and development of novel first-in-class antibody therapeutics for the treatment of cancer, autoimmune, and other serious diseases. Dren Bio’s lead product candidate, DR-01, is currently being evaluated in oncology and autoimmune indications. In addition, Dren Bio’s targeted myeloid engager and phagocytosis platform is a bispecific antibody-based technology that induces potent depletion of disease-causing agents by engaging a novel phagocytic receptor that is selectively expressed on myeloid cells and activated only in the presence of the target antigen. For more information about Dren Bio and its current development pipeline, please visit Dren Bio’s website at www.drenbio.com.
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Citations:
[1] https://www.globenewswire.com/news-release/2024/04/09/2860387/0/en/IN8bio-Announces-New-Preclinical-Data-for-Gamma-Delta-nsCAR-T-Cell-Therapy-Platform-at-AACR-2024.html
[2] https://investors.in8bio.com/news-releases/news-release-details/in8bio-reports-fourth-quarter-and-full-year-2024-financial
[3] https://www.rootsanalysis.com/reports/t-cell-therapies-market/261.html
[4] https://www.globenewswire.com/news-release/2025/03/13/3042590/0/en/IN8bio-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Business-Highlights.html
[5] https://www.stocktitan.net/news/INAB/in8bio-to-present-new-preclinical-data-on-novel-gamma-delta-t-cell-yokboglki3gw.html
[6] https://public.com/stocks/inab/forecast-price-target
[7] https://www.gminsights.com/industry-analysis/car-t-cell-therapy-market
[8] https://www.stocktitan.net/news/INAB/
[9] https://www.biospace.com/press-releases/in8bio-to-present-new-preclinical-data-on-novel-gamma-delta-%CE%B3%CE%B4-t-cell-engager-platform-for-cancer-immunotherapy-at-aacr-annual-meeting-2025
[10] https://www.benzinga.com/quote/INAB/analyst-ratings
[11] https://www.globenewswire.com/news-release/2025/03/25/3048565/0/en/T-Cell-Therapy-Market-Research-2025-Over-10-Approved-Therapies-and-More-than-1-200-Preclinical-Clinical-Therapy-Candidates-Global-Industry-Trends-and-Forecasts-to-2035.html
[12] https://investors.in8bio.com/news-events/press-releases
[13] https://www.globenewswire.com/news-release/2025/03/31/3052244/0/en/IN8bio-to-Present-New-Preclinical-Data-on-Novel-Gamma-Delta-%CE%B3%CE%B4-T-cell-Engager-Platform-for-Cancer-Immunotherapy-at-AACR-Annual-Meeting-2025.html
[14] https://www.nasdaq.com/market-activity/stocks/inab/analyst-research
[15] https://finance.yahoo.com/news/t-cell-therapy-market-research-104600820.html
[16] https://investors.in8bio.com/news-releases/news-release-details/in8bio-reports-updated-positive-results-phase-1-trial-inb-100
[17] https://in8bio.com
[18] https://www.wsj.com/market-data/quotes/INAB/research-ratings
[19] https://crisprmedicinenews.com/press-release-service/card/car-t-cell-therapy-market-research-2024-2025-size-forecasts-trials-and-trends-approved-car-t-t/
[20] https://www.biospace.com/press-releases/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml
